The condition is characterised by periods of active inflammation (flares) and remission
Alternatively, you can take our online medical consultation to find out instantly if you're eligible
Consider: More frequent assessments during dose escalation (first 4-5 months) to evaluate tolerability, side effects, and any changes in lupus disease activity Regular reviews once on maintenance dosing, coordinated with routine rheumatology appointments where possible Weight and BMI tracking to assess treatment efficacy Blood pressure monitoring at consultations, as weight loss should improve hypertension but requires documentation Laboratory monitoring should be tailored to individual risk factors: Renal function tests (creatinine, eGFR, urinalysis) as appropriate for the patient's baseline renal status, with increased frequency if significant gastrointestinal side effects occur Lupus disease markers (complement levels, anti-dsDNA antibodies, inflammatory markers) as per the patient's usual monitoring schedule, with additional testing if symptoms suggest a flare Lipid profile and HbA1c to track metabolic improvements INR monitoring for patients on warfarin, particularly when starting or adjusting semaglutide dosing Thyroid function tests for patients on levothyroxine Patient safety advice is paramount
Every batch is synthesized to meet a minimum purity standard of 98%
It is not currently approved to treat cirrhosis
If you have experienced semaglutide bloating , semaglutide acid reflux , or semaglutide constipation , you understand how significantly this medication can disrupt your digestive system
